Laboratory Considerations for Clinical Trials
Science:Life Sciences
A liquid biopsy is a minimally invasive alternative to a more traditional surgical solid tumor biopsy.
In this episode, Dr. Stephanie Hastings, genomics product lead at Q Squared Solutions, lays out the considerations for liquid biopsy collection and the type of information that can be gathered from circulating free DNA (cfDNA).
The main approaches comprise for evaluating cfDNA are:
- specific mutation detection to help support targeted therapies
- broader sequencing technologies to enable biomarker evaluations
- custom sequencing panels to support clinical trial assay development
She describes the typical panels for each of the approaches, the sample collection requirements and how these analyses are implemented on a global scale.
More Episodes
What is the Role of Digital Pathology in Clinical Trials
2023-11-17
266
2023-11-17
266
Flexible Approaches for Biotech Companies in Clinical Trials
2022-06-22
304
2022-06-22
304
Risk Management for Biotech Companies in Clinical Trials
2022-05-16
239
2022-05-16
239
Managing Sample Data from Vendors
2021-09-14
268
2021-09-14
268
Automation within an ADME Laboratory
2021-08-26
222
2021-08-26
222
Bioanalytical Automation of Samples
2021-07-30
197
2021-07-30
197
Consent Tracking for Clinical Samples
2021-07-28
200
2021-07-28
200
Tracking Clinical Trial Samples
2021-07-28
193
2021-07-28
193
Avoiding Canceled Tests in Pediatric Samples
2021-02-02
157
2021-02-02
157
Covid Vaccine Testing
2020-09-15
205
2020-09-15
205
Hybrid Assays for Protein Bioanalysis
2020-07-29
169
2020-07-29
169
High Throughput ADME Testing
2020-07-29
114
2020-07-29
114
Get this podcast on your
phone, FREE
